Brufsky, Adam
Liu, Raymond
Ryan, Joanne C.
Article History
Received: 24 December 2024
Accepted: 25 July 2025
First Online: 11 September 2025
Change Date: 26 September 2025
Change Type: Update
Change Details: The original online version of this article was revised. Due to a typesetting mistake, the title in the original article was published incorrectly. The title “Part 3 (Podcast): From Non-believer to Believer: A Podcast Conversation on the Journey from Skeptic to Proponent of Oncology Real-World Evidence” has now been corrected to “Non-believer to Believer: A Podcast Conversation on the Journey from Skeptic to Proponent of Oncology Real-World Evidence”.
Change Date: 25 September 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s40487-025-00382-y
Declarations
:
: Adam Brufsky reports receiving grants from Agendia and AstraZeneca; and consulting fees or honoraria from AstraZeneca, Pfizer, Novartis, Lilly, Genentech/Roche, Seagen, Daiichi-Sankyo, Merck, Agendia, Sanofi, and Puma. Raymond Liu reports travel, accommodation, and expenses from Pfizer; and institutional research funding from Genentech, AstraZeneca, Exact Sciences, Biotheranostics, and BeiGene. Joanne C. Ryan is an employee of and stockholder in Pfizer Inc.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. The podcast transcript has been edited for clarity.